6Y4 Stock Overview
A clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Vicore Pharma Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.79 |
| 52 Week High | SEK 2.01 |
| 52 Week Low | SEK 1.06 |
| Beta | 0.76 |
| 11 Month Change | 10.22% |
| 3 Month Change | 40.28% |
| 1 Year Change | 21.27% |
| 33 Year Change | -9.41% |
| 5 Year Change | n/a |
| Change since IPO | 2.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6Y4 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 4.9% | -0.5% | 0.8% |
| 1Y | 21.3% | -18.9% | 2.0% |
Return vs Industry: 6Y4 exceeded the German Biotechs industry which returned -18.9% over the past year.
Return vs Market: 6Y4 exceeded the German Market which returned 2% over the past year.
Price Volatility
| 6Y4 volatility | |
|---|---|
| 6Y4 Average Weekly Movement | 8.9% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 6Y4's share price has been volatile over the past 3 months.
Volatility Over Time: 6Y4's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 26 | Ahmed Mousa | www.vicorepharma.com |
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases. It develops C21, an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. The company is also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis.
Vicore Pharma Holding AB (publ) Fundamentals Summary
| 6Y4 fundamental statistics | |
|---|---|
| Market cap | €210.64m |
| Earnings (TTM) | -€18.76m |
| Revenue (TTM) | €9.18m |
22.9x
P/S Ratio-11.2x
P/E RatioIs 6Y4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6Y4 income statement (TTM) | |
|---|---|
| Revenue | SEK 104.24m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 104.24m |
| Other Expenses | SEK 317.18m |
| Earnings | -SEK 212.94m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 22, 2024
| Earnings per share (EPS) | -1.91 |
| Gross Margin | 100.00% |
| Net Profit Margin | -204.27% |
| Debt/Equity Ratio | 0% |
How did 6Y4 perform over the long term?
See historical performance and comparison